Conditional transgenic mice expressing C-terminally truncated human α-synuclein (αSyn119) exhibit reduced striatal dopamine without loss of nigrostriatal pathway dopaminergic neurons

Molecular Neurodegeneration

Volumn 4, Issue 1, 2009, Pages

  Daher, João Paulo L ^a,b   Ying, Mingyao ^a   Banerjee, Rebecca ^c   McDonald, Rebecca S ^c   Hahn, Myriam Dumas ^b   Yang, Lichuan ^c   Beal, M Flint ^c   Thomas, Bobby ^c   Dawson, Valina L ^a   Dawson, Ted M ^a   Moore, Darren J ^a,d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d EPFL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 5 HYDROXYINDOLEACETIC ACID; ALPHA SYNUCLEIN; BIOGENIC AMINE; CRE RECOMBINASE; DOPAMINE; HOMOVANILLIC ACID; NORADRENALIN; SEROTONIN;

ALPHA SYNUCLEIN GENE; ANIMAL CELL; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; GENE; GENETIC VARIABILITY; HUMAN; HUMAN CELL; MISSENSE MUTATION; MOUSE; NEUROCHEMISTRY; NEUROPATHOLOGY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PROTEIN EXPRESSION; STRIATONIGRAL DEGENERATION; TRANSGENIC MOUSE;

MURINAE; MUS; MUS MUSCULUS;

EID: 69049119262     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/1750-1326-4-34     Document Type: Article

References (48)

1. Parkinson's disease. Second of two parts. AE Lang AM Lozano, N Engl J Med 1998 339 16 1130 1143 10.1056/NEJM199810153391607 9770561
2. Parkinson's disease. First of two parts. AE Lang AM Lozano, N Engl J Med 1998 339 15 1044 1053 10.1056/NEJM199810083391506 9761807
3. Staging of brain pathology related to sporadic Parkinson's disease. H Braak K Del Tredici U Rub RA de Vos EN Jansen Steur E Braak, Neurobiol Aging 2003 24 2 197 211 10.1016/S0197-4580(02)00065-9 12498954
4. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. MG Spillantini RA Crowther R Jakes M Hasegawa M Goedert, Proc Natl Acad Sci USA 1998 95 11 6469 6473 9600990 10.1073/pnas.95.11.6469
5. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease [letter]. R Kruger W Kuhn T Muller D Woitalla M Graeber S Kosel H Przuntek JT Epplen L Schols O Riess, Nat Genet 1998 18 2 106 108 10.1038/ng0298-106 9462735
6. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease [see comments]. MH Polymeropoulos C Lavedan E Leroy SE Ide A Dehejia A Dutra B Pike H Root J Rubenstein R Boyer ES Stenroos S Chandrasekharappa A Athanassiadou T Papapetropoulos WG Johnson AM Lazzarini RC Duvoisin G Di Iorio LI Golbe RL Nussbaum, Science 1997 276 5321 2045 2047 10.1126/science.276.5321.2045 9197268
7. alpha-Synuclein locus triplication causes Parkinson's disease. AB Singleton M Farrer J Johnson A Singleton S Hague J Kachergus M Hulihan T Peuralinna A Dutra R Nussbaum S Lincoln A Crawley M Hanson D Maraganore C Adler MR Cookson M Muenter M Baptista D Miller J Blancato J Hardy K Gwinn-Hardy, Science 2003 302 5646 841 10.1126/science.1090278 14593171
8. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. JJ Zarranz J Alegre JC Gomez-Esteban E Lezcano R Ros I Ampuero L Vidal J Hoenicka O Rodriguez B Atares V Llorens E Gomez Tortosa T del Ser DG Munoz JG de Yebenes, Ann Neurol 2004 55 2 164 173 10.1002/ana.10795 14755719
9. Mendelian forms of Parkinson's disease. T Gasser, Biochim Biophys Acta 2009 1792 7 587 586 19168133
10. Molecular mechanisms of alpha-synuclein neurodegeneration. EA Waxman BI Giasson, Biochim Biophys Acta 2008 1792 7 616 624 18955133
11. alpha-Synuclein is phosphorylated in synucleinopathy lesions. H Fujiwara M Hasegawa N Dohmae A Kawashima E Masliah MS Goldberg J Shen K Takio T Iwatsubo, Nat Cell Biol 2002 4 2 160 164 11813001
12. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. BI Giasson JE Duda IV Murray Q Chen JM Souza HI Hurtig H Ischiropoulos JQ Trojanowski VM Lee, Science 2000 290 5493 985 989 10.1126/science.290.5493.985 11062131
13. Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. W Li N West E Colla O Pletnikova JC Troncoso L Marsh TM Dawson P Jakala T Hartmann DL Price MK Lee, Proc Natl Acad Sci USA 2005 102 6 2162 2167 15684072 10.1073/pnas.0406976102
14. Value of genetic models in understanding the cause and mechanisms of Parkinson's disease. DJ Moore TM Dawson, Curr Neurol Neurosci Rep 2008 8 4 288 296 10.1007/s11910-008-0045-7 18590612
15. alpha-Synucleinopathy models and human neuropathology: similarities and differences. PJ Kahle, Acta Neuropathol 2008 115 1 87 95 10.1007/s00401-007- 0302-x 17932682
16. In vivo alpha-synuclein overexpression in rodents: a useful model of Parkinson's disease? MF Chesselet, Exp Neurol 2008 209 1 22 27 17949715 10.1016/j.expneurol.2007.08.006
17. Neuronal a-synucleinopathy with sever movement disorder in micer expressing A53T human a-synuclein. BI Giasson JE Duda SM Quinn B Zhang JQ Trojanowski VM-Y Lee, Neuron 2002 34 521 533 10.1016/S0896-6273(02)00682-7 12062037
18. Motor dysfunction and gliosis with preserved dopaminergic markers in human alpha-synuclein A30P transgenic mice. T Gomez-Isla MC Irizarry A Mariash B Cheung O Soto S Schrump J Sondel L Kotilinek J Day MA Schwarzschild JH Cha K Newell DW Miller K Ueda AB Young BT Hyman KH Ashe, Neurobiol Aging 2003 24 2 245 258 10.1016/S0197-4580(02)00091-X 12498958
19. Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 - > Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. MK Lee W Stirling Y Xu X Xu D Qui AS Mandir TM Dawson NG Copeland NA Jenkins DL Price, Proc Natl Acad Sci USA 2002 99 13 8968 8973 12084935 10.1073/pnas.132197599
20. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. E Masliah E Rockenstein I Veinbergs M Mallory M Hashimoto A Takeda Y Sagara A Sisk L Mucke, Science 2000 287 5456 1265 1269 10.1126/science.287.5456.1265 10678833
21. Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. M Neumann PJ Kahle BI Giasson L Ozmen E Borroni W Spooren V Muller S Odoy H Fujiwara M Hasegawa T Iwatsubo JQ Trojanowski HA Kretzschmar C Haass, J Clin Invest 2002 110 10 1429 1439 12438441
22. Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters. E Rockenstein M Mallory M Hashimoto D Song CW Shults I Lang E Masliah, J Neurosci Res 2002 68 5 568 578 10.1002/jnr.10231 12111846
23. Neuropathology in mice expressing human alpha-synuclein. H van der Putten KH Wiederhold A Probst S Barbieri C Mistl S Danner S Kauffmann K Hofele WP Spooren MA Ruegg S Lin P Caroni B Sommer M Tolnay G Bilbe, J Neurosci 2000 20 16 6021 6029 10934251
24. Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice. EK Richfield MJ Thiruchelvam DA Cory-Slechta C Wuertzer RR Gainetdinov MG Caron DA Di Monte HJ Federoff, Exp Neurol 2002 175 1 35 48 10.1006/exnr.2002.7882 12009758
25. Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human alpha-synuclein(1-120) : implications for Lewy body disorders. GK Tofaris P Garcia Reitbock T Humby SL Lambourne M O'Connell B Ghetti H Gossage PC Emson LS Wilkinson M Goedert MG Spillantini, J Neurosci 2006 26 15 3942 3950 10.1523/JNEUROSCI.4965-05.2006 16611810
26. Selective loss of nigral dopamine neurons induced by overexpression of truncated human alpha-synuclein in mice. M Wakamatsu A Ishii S Iwata J Sakagami Y Ukai M Ono D Kanbe S Muramatsu K Kobayashi T Iwatsubo M Yoshimoto, Neurobiol Aging 2008 29 4 574 585 10.1016/j.neurobiolaging.2006.11.017 17174013
27. Lack of nigral pathology in transgenic mice expressing human alpha-synuclein driven by the tyrosine hydroxylase promoter. Y Matsuoka M Vila S Lincoln A McCormack M Picciano J LaFrancois X Yu D Dickson WJ Langston E McGowan M Farrer J Hardy K Duff S Przedborski DA Di Monte, Neurobiol Dis 2001 8 3 535 539 10.1006/nbdi.2001.0392 11442360
28. Risk factors for dopaminergic neuron loss in human alpha-synuclein transgenic mice. MJ Thiruchelvam JM Powers DA Cory-Slechta EK Richfield, Eur J Neurosci 2004 19 4 845 854 10.1111/j.0953-816X.2004.03139.x 15009131
29. A precipitating role for truncated alpha-synuclein and the proteasome in alpha-synuclein aggregation: implications for pathogenesis of Parkinson disease. CW Liu BI Giasson KA Lewis VM Lee GN Demartino PJ Thomas, J Biol Chem 2005 280 24 22670 22678 10.1074/jbc.M501508200 15840579
30. Synthetic filaments assembled from C-terminally truncated alpha-synuclein. RA Crowther R Jakes MG Spillantini M Goedert, FEBS Lett 1998 436 3 309 312 10.1016/S0014-5793(98)01146-6 9801138
31. Role of alpha-synuclein carboxy-terminus on fibril formation in vitro. IV Murray BI Giasson SM Quinn V Koppaka PH Axelsen H Ischiropoulos JQ Trojanowski VM Lee, Biochemistry 2003 42 28 8530 8540 10.1021/bi027363r 12859200
32. Pathological cell-cell interactions elicited by a neuropathogenic form of mutant Huntingtin contribute to cortical pathogenesis in HD mice. X Gu C Li W Wei V Lo S Gong SH Li T Iwasato S Itohara XJ Li I Mody N Heintz XW Yang, Neuron 2005 46 3 433 444 10.1016/j.neuron.2005.03.025 15882643
33. Generalized lacZ expression with the ROSA26 Cre reporter strain. P Soriano, Nat Genet 1999 21 1 70 71 10.1038/5007 9916792
34. Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus. S Srinivas T Watanabe CS Lin CM William Y Tanabe TM Jessell F Costantini, BMC Dev Biol 2001 1 4 11299042 10.1186/1471-213X-1-4
35. Bcl-x is required for proper development of the mouse substantia nigra. JM Savitt SS Jang W Mu VL Dawson TM Dawson, J Neurosci 2005 25 29 6721 6728 10.1523/JNEUROSCI.0760-05.2005 16033881
36. Disruption of the glucocorticoid receptor gene in the nervous system results in reduced anxiety. F Tronche C Kellendonk O Kretz P Gass K Anlag PC Orban R Bock R Klein G Schutz, Nat Genet 1999 23 1 99 103 10.1038/12703 10471508
37. Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. DD Murphy SM Rueter JQ Trojanowski VM Lee, J Neurosci 2000 20 9 3214 3220 10777786
38. Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. LJ Martin Y Pan AC Price W Sterling NG Copeland NA Jenkins DL Price MK Lee, J Neurosci 2006 26 1 41 50 10.1523/JNEUROSCI.4308-05.2006 16399671
39. Distinct cleavage patterns of normal and pathologic forms of alpha-synuclein by calpain I in vitro. AJ Mishizen-Eberz RP Guttmann BI Giasson GA Day 3rd R Hodara H Ischiropoulos VM Lee JQ Trojanowski DR Lynch, J Neurochem 2003 86 4 836 47 10.1046/j.1471-4159.2003.01878.x 12887682
40. Cleavage of alpha-synuclein by calpain: potential role in degradation of fibrillized and nitrated species of alpha-synuclein. AJ Mishizen-Eberz EH Norris BI Giasson R Hodara H Ischiropoulos VM Lee JQ Trojanowski DR Lynch, Biochemistry 2005 44 21 7818 29 10.1021/bi047846q 15909996
41. Calpain-cleavage of alpha-synuclein: connecting proteolytic processing to disease-linked aggregation. BM Dufty LR Warner ST Hou SX Jiang T Gomez-Isla KM Leenhouts JT Oxford MB Feany E Masliah TT Rohn, Am J Pathol 2007 170 5 1725 38 17456777 10.2353/ajpath.2007.061232
42. Cathepsin D is the main lysosomal enzyme involved in the degradation of alpha-synuclein and generation of its carboxy-terminally truncated species. D Sevlever P Jiang SH Yen, Biochemistry 2008 47 36 9678 87 10.1021/bi800699v 18702517
43. Enhanced vulnerability to oxidative stress by alpha-synuclein mutations and C-terminal truncation. S Kanda JF Bishop MA Eglitis Y Yang MM Mouradian, Neuroscience 2000 97 2 279 84 10.1016/S0306-4522(00)00077-4 10799759
44. Disruption of overlapping transcripts in the ROSA beta geo 26 gene trap strain leads to widespread expression of beta-galactosidase in mouse embryos and hematopoietic cells. BP Zambrowicz A Imamoto S Fiering LA Herzenberg WG Kerr P Soriano, Proc Natl Acad Sci USA 1997 94 8 3789 3794 9108056 10.1073/pnas.94.8. 3789
45. MPTP as a mitochondrial neurotoxic model of Parkinson's disease. S Przedborski K Tieu C Perier M Vila, J Bioenerg Biomembr 2004 36 4 375 379 10.1023/B:JOBB.0000041771.66775.d5 15377875
46. Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism. AS Mandir S Przedborski V Jackson-Lewis ZQ Wang CM Simbulan-Rosenthal ME Smulson BE Hoffman DB Guastella VL Dawson TM Dawson, Proc Natl Acad Sci USA 1999 96 10 5774 5779 10318960 10.1073/pnas.96.10.5774
47. New stereological methods for counting neurons. MJ West, Neurobiol Aging 1993 14 4 275 285 10.1016/0197-4580(93)90112-O 8367009
48. MPTP and DSP-4 susceptibility of substantia nigra and locus coeruleus catecholaminergic neurons in mice is independent of parkin activity. B Thomas R von Coelln AS Mandir DB Trinkaus MH Farah K Leong Lim NY Calingasan M Flint Beal VL Dawson TM Dawson, Neurobiol Dis 2007 26 2 312 322 17336077 10.1016/j.nbd.2006.12.021